Erasca (ERAS) Competitors $1.55 -0.06 (-3.73%) Closing price 04:00 PM EasternExtended Trading$1.56 +0.00 (+0.32%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS vs. SRPT, MESO, APGE, CDTX, BEAM, BHVN, TWST, IMCR, AUPH, and TVTXShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Sarepta Therapeutics (SRPT), Mesoblast (MESO), Apogee Therapeutics (APGE), Cidara Therapeutics (CDTX), Beam Therapeutics (BEAM), Biohaven (BHVN), Twist Bioscience (TWST), Immunocore (IMCR), Aurinia Pharmaceuticals (AUPH), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Its Competitors Sarepta Therapeutics Mesoblast Apogee Therapeutics Cidara Therapeutics Beam Therapeutics Biohaven Twist Bioscience Immunocore Aurinia Pharmaceuticals Travere Therapeutics Erasca (NASDAQ:ERAS) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment. Is ERAS or SRPT more profitable? Erasca has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.34%. Sarepta Therapeutics' return on equity of -1.03% beat Erasca's return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -31.19% -26.34% Sarepta Therapeutics -2.34%-1.03%-0.37% Does the media refer more to ERAS or SRPT? In the previous week, Sarepta Therapeutics had 7 more articles in the media than Erasca. MarketBeat recorded 14 mentions for Sarepta Therapeutics and 7 mentions for Erasca. Sarepta Therapeutics' average media sentiment score of 1.37 beat Erasca's score of 0.69 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, ERAS or SRPT? Sarepta Therapeutics has higher revenue and earnings than Erasca. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$161.65M-$0.45-3.44Sarepta Therapeutics$1.90B0.88$235.24M-$0.87-19.79 Do insiders and institutionals believe in ERAS or SRPT? 67.8% of Erasca shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 14.4% of Erasca shares are owned by company insiders. Comparatively, 7.6% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, ERAS or SRPT? Erasca has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Do analysts rate ERAS or SRPT? Erasca currently has a consensus price target of $3.71, indicating a potential upside of 139.63%. Sarepta Therapeutics has a consensus price target of $42.36, indicating a potential upside of 145.99%. Given Sarepta Therapeutics' higher possible upside, analysts clearly believe Sarepta Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57Sarepta Therapeutics 6 Sell rating(s) 15 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.07 SummarySarepta Therapeutics beats Erasca on 9 of the 15 factors compared between the two stocks. Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$439.69M$3.15B$5.78B$10.04BDividend YieldN/A2.28%5.27%4.52%P/E Ratio-3.4421.4475.5726.08Price / SalesN/A427.98516.51171.66Price / CashN/A45.5837.2059.76Price / Book1.039.6011.536.20Net Income-$161.65M-$53.33M$3.29B$270.65M7 Day Performance8.39%0.61%0.44%2.77%1 Month Performance10.71%11.11%10.84%8.83%1 Year Performance-50.00%12.61%61.62%27.49% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca2.3238 of 5 stars$1.55-3.7%$3.71+139.6%-47.6%$439.69MN/A-3.44120SRPTSarepta Therapeutics4.7324 of 5 stars$18.20-0.8%$43.50+139.0%-86.2%$1.78B$1.90B-20.92840Positive NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeMESOMesoblast1.5001 of 5 stars$13.83-13.3%$18.00+30.2%+144.3%$1.77B$5.90M0.0080High Trading VolumeAPGEApogee Therapeutics2.8843 of 5 stars$36.37-0.7%$97.29+167.5%-19.0%$1.68BN/A-8.8191Positive NewsCDTXCidara Therapeutics3.7166 of 5 stars$65.39+0.2%$64.14-1.9%+438.1%$1.66B$1.27M-5.8890Positive NewsBEAMBeam Therapeutics2.4462 of 5 stars$16.36-2.9%$48.45+196.2%-13.0%$1.66B$63.52M-3.64510BHVNBiohaven3.4935 of 5 stars$15.35-1.1%$54.23+253.2%-60.2%$1.63BN/A-2.00239Trending NewsTWSTTwist Bioscience3.7564 of 5 stars$26.97+1.4%$49.40+83.2%-32.7%$1.63B$312.97M-18.60990News CoveragePositive NewsIMCRImmunocore1.5376 of 5 stars$32.22-0.1%$56.89+76.6%+8.0%$1.62B$310.20M-80.55320Positive NewsAUPHAurinia Pharmaceuticals2.7854 of 5 stars$11.99-0.7%$12.00+0.1%+79.8%$1.58B$235.13M27.88300News CoveragePositive NewsTVTXTravere Therapeutics2.3026 of 5 stars$17.50-1.1%$33.43+91.0%+68.3%$1.56B$233.18M-8.58460Trending NewsAnalyst ForecastOptions VolumeGap Up Related Companies and Tools Related Companies Sarepta Therapeutics Alternatives Mesoblast Alternatives Apogee Therapeutics Alternatives Cidara Therapeutics Alternatives Beam Therapeutics Alternatives Biohaven Alternatives Twist Bioscience Alternatives Immunocore Alternatives Aurinia Pharmaceuticals Alternatives Travere Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERAS) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ERAS Stock Alerts